Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr;40(4):161.e1-161.e7.
doi: 10.1016/j.urolonc.2021.08.007. Epub 2021 Aug 29.

A machine learning approach to predict progression on active surveillance for prostate cancer

Affiliations

A machine learning approach to predict progression on active surveillance for prostate cancer

Madhur Nayan et al. Urol Oncol. 2022 Apr.

Abstract

Purpose: Robust prediction of progression on active surveillance (AS) for prostate cancer can allow for risk-adapted protocols. To date, models predicting progression on AS have invariably used traditional statistical approaches. We sought to evaluate whether a machine learning (ML) approach could improve prediction of progression on AS.

Patients and methods: We performed a retrospective cohort study of patients diagnosed with very-low or low-risk prostate cancer between 1997 and 2016 and managed with AS at our institution. In the training set, we trained a traditional logistic regression (T-LR) classifier, and alternate ML classifiers (support vector machine, random forest, a fully connected artificial neural network, and ML-LR) to predict grade-progression. We evaluated model performance in the test set. The primary performance metric was the F1 score.

Results: Our cohort included 790 patients. With a median follow-up of 6.29 years, 234 developed grade-progression. In descending order, the F1 scores were: support vector machine 0.586 (95% CI 0.579 - 0.591), ML-LR 0.522 (95% CI 0.513 - 0.526), artificial neural network 0.392 (95% CI 0.379 - 0.396), random forest 0.376 (95% CI 0.364 - 0.380), and T-LR 0.182 (95% CI 0.151 - 0.185). All alternate ML models had a significantly higher F1 score than the T-LR model (all p <0.001).

Conclusion: In our study, ML methods significantly outperformed T-LR in predicting progression on AS for prostate cancer. While our specific models require further validation, we anticipate that a ML approach will help produce robust prediction models that will facilitate individualized risk-stratification in prostate cancer AS.

Keywords: Active surveillance; Artificial intelligence; Machine learning; Progression; Prostatic neoplasm.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
F1 scores of machine learning and traditional statistical models predicting progression on active surveillance for prostate cancer.
Fig. 2.
Fig. 2.
Confusion matrices for models predicting progression on active surveillance for prostate cancer. Abbreviations: FN: false-negative; FP: false-positive; TN: true-negative; TP: true-positive.

References

    1. Hugosson J, Godtman RA, Carlsson SV, et al. Eighteen-year follow-up of the göteborg randomized population-based prostate cancer screening trial: effect of sociodemographic variables on participation, prostate cancer incidence and mortality. Scand J Urol 2018;52:27. - PMC - PubMed
    1. Pinsky PF, Miller E, Prorok P, et al. Extended follow-up for prostate cancer incidence and mortality among participants in the prostate, lung, colorectal and ovarian randomized cancer screening trial. BJU Int 2019;123:854. - PMC - PubMed
    1. Tosoian JJ, Mamawala M, Epstein JI, et al. Intermediate and longer-term outcomes from a prospective active-surveillance program for favorable-risk prostate cancer. J Clin Oncol 2015;33:3379. - PMC - PubMed
    1. Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med 2016;375:1415. - PubMed
    1. Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer-2020 update. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2021;79(2):243–62. - PubMed